Free Trial

Oncolytics Biotech (ONCY) 10K Form and Latest SEC Filings 2026

Oncolytics Biotech logo
$0.92 -0.01 (-1.36%)
Closing price 04:00 PM Eastern
Extended Trading
$0.89 -0.02 (-2.62%)
As of 07:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Oncolytics Biotech SEC Filings & Recent Activity

Oncolytics Biotech (NASDAQ:ONCY) has submitted 378+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form 8-K submitted on May 4, 2026.

Form 4
ONCOLYTICS BIOTECH INC Reports Ownership Change on Mar. 13, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Oncolytics Biotech Files Current Report on May. 4, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

20-F
Oncolytics Biotech Files Annual Report on Mar. 7, 2025

The 20-F contains Oncolytics Biotech's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Oncolytics Biotech SEC Filing History

Browse Oncolytics Biotech's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/04/2026 8:03 AM
Oncolytics Biotech (1129928) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/27/2026 7:16 AM
Oncolytics Biotech (1129928) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/08/2026 4:03 PM
Oncolytics Biotech (1129928) Filer
Form AW
04/08/2026 4:03 PM
Oncolytics Biotech (1129928) Filer
Form AW
04/08/2026 4:03 PM
Oncolytics Biotech (1129928) Filer
Form AW
04/08/2026 4:03 PM
Oncolytics Biotech (1129928) Filer
Form AW
04/08/2026 4:03 PM
Oncolytics Biotech (1129928) Filer
Form AW
04/08/2026 4:03 PM
Oncolytics Biotech (1129928) Filer
Form AW
04/08/2026 4:03 PM
Oncolytics Biotech (1129928) Filer
Form AW
04/08/2026 4:03 PM
Oncolytics Biotech (1129928) Filer
Form AW
04/08/2026 4:03 PM
Oncolytics Biotech (1129928) Filer
Form AW
04/08/2026 4:03 PM
Oncolytics Biotech (1129928) Filer
Form AW
04/08/2026 4:04 PM
Oncolytics Biotech (1129928) Filer
Form F-10POS
04/08/2026 4:04 PM
Oncolytics Biotech (1129928) Filer
Form F-10POS
04/08/2026 4:04 PM
Oncolytics Biotech (1129928) Filer
Form F-10POS
04/08/2026 4:04 PM
Oncolytics Biotech (1129928) Filer
Form F-10POS
04/08/2026 4:04 PM
Oncolytics Biotech (1129928) Filer
Form F-10POS
04/08/2026 4:04 PM
Oncolytics Biotech (1129928) Filer
Form F-10POS
04/08/2026 4:04 PM
Oncolytics Biotech (1129928) Filer
Form F-10POS
04/08/2026 4:04 PM
Oncolytics Biotech (1129928) Filer
Form F-10POS
04/08/2026 4:04 PM
Oncolytics Biotech (1129928) Filer
Form F-10POS
04/08/2026 4:04 PM
Oncolytics Biotech (1129928) Filer
Form F-10POS
04/06/2026 4:20 PM
Oncolytics Biotech (1129928) Filer
Form F-10POS
04/06/2026 4:20 PM
Oncolytics Biotech (1129928) Filer
Form F-10POS
04/06/2026 4:20 PM
Oncolytics Biotech (1129928) Filer
Form F-10POS
04/06/2026 4:20 PM
Oncolytics Biotech (1129928) Filer
Form F-10POS
04/06/2026 4:20 PM
Oncolytics Biotech (1129928) Filer
Form F-10POS
04/06/2026 4:20 PM
Oncolytics Biotech (1129928) Filer
Form F-10POS
04/06/2026 4:20 PM
Oncolytics Biotech (1129928) Filer
Form F-10POS
04/06/2026 4:20 PM
Oncolytics Biotech (1129928) Filer
Form F-10POS
04/06/2026 4:20 PM
Oncolytics Biotech (1129928) Filer
Form F-10POS
04/06/2026 4:20 PM
Oncolytics Biotech (1129928) Filer
Form F-10POS
04/06/2026 3:11 PM
Oncolytics Biotech (1129928) Filer
Form 424B5
04/06/2026 3:12 PM
Oncolytics Biotech (1129928) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/06/2026 8:24 AM
Oncolytics Biotech (1129928) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/05/2026 11:15 PM
Oncolytics Biotech (1129928) Filer
Form EFFECT
04/01/2026 11:15 PM
Oncolytics Biotech (1129928) Filer
Form EFFECT
04/01/2026 8:07 AM
Oncolytics Biotech (1129928) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/31/2026 8:48 PM
Oncolytics Biotech (1129928) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
03/31/2026 8:50 PM
Oncolytics Biotech (1129928) Filer
Form S-3
Registration statement under Securities Act of 1933  
03/31/2026 8:50 PM
Oncolytics Biotech (1129928) Filer
Form POS AM
03/31/2026 8:51 PM
Oncolytics Biotech (1129928) Filer
Form S-8 POS
03/31/2026 8:51 PM
Oncolytics Biotech (1129928) Filer
Form S-8 POS
03/31/2026 8:54 PM
Oncolytics Biotech (1129928) Filer
Form F-10POS
03/31/2026 8:54 PM
Oncolytics Biotech (1129928) Filer
Form F-10POS
03/31/2026 8:55 PM
Oncolytics Biotech (1129928) Filer
Form F-10POS
03/31/2026 8:55 PM
Oncolytics Biotech (1129928) Filer
Form F-10POS
03/31/2026 8:55 PM
Oncolytics Biotech (1129928) Filer
Form F-10POS
03/31/2026 8:55 PM
Oncolytics Biotech (1129928) Filer
Form F-10POS
03/31/2026 8:56 PM
Oncolytics Biotech (1129928) Filer
Form F-10POS
03/31/2026 8:56 PM
Oncolytics Biotech (1129928) Filer
Form F-10POS
03/31/2026 8:57 PM
Oncolytics Biotech (1129928) Filer
Form F-10POS
03/31/2026 8:57 PM
Oncolytics Biotech (1129928) Filer
Form F-10POS
03/20/2026 3:43 PM
Oncolytics Biotech (1129928) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/19/2026 8:05 AM
Oncolytics Biotech (1129928) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/13/2026 7:00 AM
Kelly Jared (2103581) Reporting
Oncolytics Biotech (1129928) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/13/2026 7:00 AM
Oncolytics Biotech (1129928) Issuer
Parsons James T. (1759855) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/02/2026 9:44 AM
Oncolytics Biotech (1129928) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/24/2026 8:10 AM
Oncolytics Biotech (1129928) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/13/2026 6:00 AM
Andrews Patricia S (1445710) Reporting
Oncolytics Biotech (1129928) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/13/2026 6:00 AM
Aromando Andrew (1976455) Reporting
Oncolytics Biotech (1129928) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/13/2026 6:00 AM
Oncolytics Biotech (1129928) Issuer
Seizinger Bernd R. (1789042) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/13/2026 6:00 AM
Hagerman Allison (2103583) Reporting
Oncolytics Biotech (1129928) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/13/2026 6:00 AM
Brown Deborah Margaret (2103580) Reporting
Oncolytics Biotech (1129928) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/13/2026 6:00 AM
Heineman Thomas Charles (2103579) Reporting
Oncolytics Biotech (1129928) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/13/2026 6:00 AM
Oncolytics Biotech (1129928) Issuer
Pisano Wayne (1743611) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/13/2026 6:00 AM
Look Kirk (2103582) Reporting
Oncolytics Biotech (1129928) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/13/2026 6:00 AM
Kelly Jared (2103581) Reporting
Oncolytics Biotech (1129928) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/04/2026 11:05 AM
Oncolytics Biotech (1129928) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/20/2026 3:30 PM
Oncolytics Biotech (1129928) Issuer
Seizinger Bernd R. (1789042) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/12/2026 3:05 PM
Oncolytics Biotech (1129928) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/09/2026 8:18 AM
Oncolytics Biotech (1129928) Subject
Form 425
01/07/2026 8:04 AM
Oncolytics Biotech (1129928) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/02/2026 3:30 PM
Oncolytics Biotech (1129928) Issuer
RIGBY JONATHAN (1356227) Reporting
Form 3
Initial statement of beneficial ownership of securities  
01/02/2026 3:30 PM
Aromando Andrew (1976455) Reporting
Oncolytics Biotech (1129928) Issuer
Form 3
Initial statement of beneficial ownership of securities  
01/02/2026 3:30 PM
Brown Deborah Margaret (2103580) Reporting
Oncolytics Biotech (1129928) Issuer
Form 3
Initial statement of beneficial ownership of securities  
01/02/2026 3:30 PM
Oncolytics Biotech (1129928) Issuer
Pisano Wayne (1743611) Reporting
Form 3
Initial statement of beneficial ownership of securities  
01/02/2026 3:30 PM
Oncolytics Biotech (1129928) Issuer
Seizinger Bernd R. (1789042) Reporting
Form 3
Initial statement of beneficial ownership of securities  
01/02/2026 3:30 PM
Oncolytics Biotech (1129928) Issuer
Parsons James T. (1759855) Reporting
Form 3
Initial statement of beneficial ownership of securities  
01/02/2026 3:30 PM
Holtham Angela (2102488) Reporting
Oncolytics Biotech (1129928) Issuer
Form 3
Initial statement of beneficial ownership of securities  
01/02/2026 3:30 PM
Heineman Thomas Charles (2103579) Reporting
Oncolytics Biotech (1129928) Issuer
Form 3
Initial statement of beneficial ownership of securities  
01/02/2026 3:30 PM
Hagerman Allison (2103583) Reporting
Oncolytics Biotech (1129928) Issuer
Form 3
Initial statement of beneficial ownership of securities  
01/02/2026 3:30 PM
Kelly Jared (2103581) Reporting
Oncolytics Biotech (1129928) Issuer
Form 3
Initial statement of beneficial ownership of securities  
01/02/2026 3:30 PM
Andrews Patricia S (1445710) Reporting
Oncolytics Biotech (1129928) Issuer
Form 3
Initial statement of beneficial ownership of securities  
01/02/2026 3:30 PM
Look Kirk (2103582) Reporting
Oncolytics Biotech (1129928) Issuer
Form 3
Initial statement of beneficial ownership of securities  
12/16/2025 8:03 AM
Oncolytics Biotech (1129928) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/09/2025 11:15 PM
Oncolytics Biotech (1129928) Filer
Form EFFECT
12/09/2025 4:26 PM
Oncolytics Biotech (1129928) Filer
Form 424B3
11/20/2025 3:06 PM
Oncolytics Biotech (1129928) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/19/2025 8:02 AM
Oncolytics Biotech (1129928) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/14/2025 2:05 PM
Anson Funds Management LP (1491072) Filed by
Oncolytics Biotech (1129928) Subject
Form SCHEDULE 13G/A
11/12/2025 4:28 PM
Oncolytics Biotech (1129928) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/04/2025 7:11 AM
Oncolytics Biotech (1129928) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/28/2025 6:43 AM
Oncolytics Biotech (1129928) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/20/2025 8:02 AM
Oncolytics Biotech (1129928) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/17/2025 8:52 PM
Oncolytics Biotech (1129928) Filer
Form F-4
Registration statement for securities of certain foreign private issuers issued in certain business combination transactions  
10/17/2025 8:54 PM
Oncolytics Biotech (1129928) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/17/2025 3:20 PM
Oncolytics Biotech (1129928) Filer
Form 424B5
10/10/2025 4:28 PM
Oncolytics Biotech (1129928) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/29/2025 8:08 AM
Oncolytics Biotech (1129928) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
(Data available from 1/1/2016 forward)

Oncolytics Biotech SEC Filings - Frequently Asked Questions

Oncolytics Biotech (ONCY) has submitted 378+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

Oncolytics Biotech's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results.

The most recent filing was a Form 8-K submitted on May 4, 2026. This was a current report on a material business event.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:ONCY) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners